Parathyroid Hormone (PTH), Intact
Parathyroid hormone (PTH) is a peptide produced by the parathyroid gland. PTH is primarily involved in the maintenance of calcium homeostasis; thus, assessment of PTH can be an important diagnostic aid for diagnosis of calcium metabolism disorders. In healthy individuals, PTH is secreted from the parathyroid gland in a negative feedback response to circulating calcium ion levels. The half-life of intact PTH is 2 to 5 minutes.
Hypercalcemia may be due to hyperparathyroidism, a group of conditions characterized by an overproduction of PTH. Hyperparathyroidism is classed as primary, secondary, and tertiary types. Primary hyperparathyroidism is most frequently due to a parathyroid tumor (usually a benign adenoma and sometimes due to parathyroid hyperplasia) that secretes PTH without feedback control, leading to hypercalcemia, kidney stones, calcium deposits in organs, and decalcification of bone. In primary hyperparathyroidism patients will generally have high calcium and high PTH levels, while phosphate levels are often low.
Secondary hyperparathyroidism is usually due to kidney failure. In secondary hyperparathyroidism, patients will generally have high PTH levels and low or normal calcium levels. Sometimes, persons with secondary hyperparathyroidism develop high serum calcium and still have high PTH; this is sometimes called tertiary hyperparathyroidism.
Hypocalcemia may be due to hypoparathyroidism – a failure of the parathyroid gland to produce sufficient PTH. Hypoparathyroidism may be due to a variety of conditions and may be persistent, progressive, or transient. Etiologies include autoimmune disorders, parathyroid damage, or removal during surgery, certain genetic conditions, and severe illnesses. Affected patients will generally have low PTH levels and low calcium levels, and will also have high phosphate levels.
Note: because of the physiologic relationship between circulating calcium and PTH, it is always important to correlate PTH results with concurrent serum calcium.
- Diagnosis of hypercalcemia due to primary hyperparathyroidism due to parathyroid tumors and non-neoplastic hyperplasia
- Diagnosis of hypercalcemia due to secondary hyperparathyroidism related to kidney disorders, malabsorption, and other calcium metabolic disorders
- Diagnosis of hypocalcemia due to hypoparathyroidism related to autoimmune disorders, injuries, surgery, and certain other disorders
Increased in:
- Primary hyperparathyroidism
- Secondary hyperparathyroidism due to renal disease, calcium deficiency, excess phosphate
- Vitamin D deficiency
- Pseudohypoparathyroidism, Types I and II
- Some drugs: anticonvulsants, lithium, phosphates
Decreased in:
- Hypoparathyroidism (autoimmune)
- DiGeorge's syndrome
- Sarcoidosis
- Wilson's Disease
- Hyperthyroidism
- Hypomagnesemia
- Malignancy with hypercalcemia
- Nonparathyroid hypercalcemia
- Parathyroidectomy
11 – 54 pg/mL (1.2 – 5.7 pmol/L)</p>
Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Serum (SST or Red)
Stability
- Ambient: Unacceptable
- Refrigerated: Unacceptable
- Frozen: 60 days
- Separate serum immediately and keep frozen.
- Clin Nephrol. 2011 Nov;76(5):348-53. [PMID: 22000553]
- Arch Surg. 2002;137:186. [PMID: 11822958]
- Surgery. 2002;131:515. [PMID: 12019404]
- Clin Chim Acta. 2004;343:167. [PMID: 15115690]
- Semin Dial. 2005; 18:296. [PMID: 16076352]